|
US2017233394A1
|
|
Stable formulations of 5,10-methylene-(6R)-tetrahydrofolic acid
|
|
KR20170015948A
|
|
Use of folates for the prevention and treatment of vascular diseases
|
|
KR20140107162A
|
|
Use of folates for the prevention and treatment of vascular diseases
|
|
KR20140081775A
|
|
Use of folates for the prevention and treatment of vascular diseases
|
|
EP2837631A1
|
|
New stable salt of 5,10-methylene-(6R)-tetrahydrofolic acid
|
|
SG11201406481TA
|
|
<sp>18</sp>F-LABELLED FOLATE/ANTIFOLATE ANALOGUES
|
|
EP2776382A1
|
|
18f-saccharide-folates
|
|
EP2766364A1
|
|
Folate conjugates of albumin-binding entities
|
|
AU2012200512A1
|
|
Crystalline forms of (6R) -L-erythro-tetrahydrobiopterin dihydrochloride
|
|
AU2009301042A1
|
|
18F-labelled folates as pet radiotracers
|
|
EP2144912A1
|
|
18 f-labelled folates
|
|
AU2008237935A1
|
|
Folate-conjugates and corresponding metal-chelate complexes for use in diagnostic imaging and radiotherapy
|
|
AU2006203758A1
|
|
Use of folates for the prevention and treatment of vascular diseases
|
|
NZ737002A
|
|
Pharmaceutical composition comprising progestogens and/or estrogens and 5-methyl-(6s)-tetrahydrofolate
|
|
AU2004311544A1
|
|
Crystalline forms of (6R) -L-erythro-tetrahydrobiopterin dihydrochloride
|
